NCT00415766

Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders

Recombinant hCG (Ovitrelle) Vesrus Urinary hCG (Pregnyl) for Triggering Final Oocyte Maturation in High Responders

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Eugonia · Academic / Other
• Sex: Female
• Age: 18 Years – 39 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to compare the clinical outcomes of recombinant human chorionic gonadotrophin (rHCG) and urinary HCG (uHCG) in patients undergoing IVF cycles.

Detailed description

Urinary human chorionic gonadotrophin (u-hCG) has been widely used to induce final oocyte maturation and to trigger ovulation in assisted conception. Recombinant technology has allowed the production of r-hCG inj which all urinary contaminants are absent. Hence, this would allow the safe subcutaneous administration of a compound with less batch-to-batch variation. This study will investigate the effectiveness of the recombinant hCG compared to the currently used urinary hCG.

Conditions

• Infertility

Interventions

Type	Name	Description
DRUG	rHCG 250ug	Injection of 250 ug Ovitrelle to trigger final oocyte maturation
DRUG	uHCG 5000 IU	Injection of 5000 IU Pregnyl to trigger final oocyte maturation
DRUG	uHCG 7500 IU	Injection of 7500 IU Pregnyl to trigger final oocyte maturation

Timeline

• Start date: 2013-06-01
• Primary completion: 2015-12-01
• Completion: 2016-07-01
• First posted: 2006-12-25
• Last updated: 2016-01-20

Locations

1 site across 1 country: Greece